[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543882":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":89,"collaborators":11,"id":91,"slug":11,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":11,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"University Hospital, Angers","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Phemop Cohort","EXPERIMENTAL",null,[13],"Diagnostic Test: Monocytes signatures in myeloproliferative neoplasms at diagnosis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","Monocytes signatures in myeloproliferative neoplasms at diagnosis","The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.",[9],[21],{"name":22,"affiliation":23,"role":24},"Agathe GOUBAND, PharmD","University Hospital","PRINCIPAL_INVESTIGATOR",[26,31],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","02 41 35 55 96","33","Agathe.Gouband@chu-angers.fr",{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},"UH Angers DRCI","+ 33 2 41 35 54 96","DRCI-Promotion-Interne@chu-angers.fr",[36,57,74],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"GOUBAND Agathe","RECRUITING","Angers","Maine et Loire","49933","France",{"type":44,"coordinates":45},"Point",[46,47],-0.55202,47.47156,{"lat":47,"lon":46},[50,51,55],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":52,"role":27,"phone":53,"phoneExt":29,"email":54},"Damien LUQUE PAZ, PharmD","02 41 35 53 53","Damien.LuquePaz@chu-angers.fr",{"name":56,"role":24,"phone":11,"phoneExt":11,"email":11},"Corentin ORVAIN, MD",{"facility":58,"status":59,"city":60,"state":40,"zip":61,"country":42,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"BESCOND Charles","NOT_YET_RECRUITING","Cholet","49325",{"type":44,"coordinates":63},[64,65],-0.87974,47.05893,{"lat":65,"lon":64},[68,72],{"name":69,"role":27,"phone":70,"phoneExt":11,"email":71},"Charles BESCOND, MD","0241355880","charles.bescond@ch-cholet.fr",{"name":73,"role":24,"phone":11,"phoneExt":11,"email":11},"Charles Bescond, MD",{"facility":75,"status":59,"city":76,"state":40,"zip":77,"country":42,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"TRUCHAN-GRACZYK Malgorzata","Saumur","49400",{"type":44,"coordinates":79},[80,81],-0.07808,47.25931,{"lat":81,"lon":80},[84,88],{"name":85,"role":27,"phone":86,"phoneExt":29,"email":87},"Malgorzata TRUCHAN-GRACZYK, MD","0241533544","matruchan@ch-saumur.fr",{"name":85,"role":24,"phone":11,"phoneExt":11,"email":11},{"type":90,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100543882",false,"NCT06361641","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP","PHEMOP","Inclusion Criteria:\n\n* Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)\n* Patient who has not received treatment specific to hemopathy at the time of sampling\n* Obtaining the signature of consent to participate in the study\n* Patient having consented to be included in the \"Malignant Hemopathy\" collection of Angers University Hospital and in FIMBANK database\n\nExclusion Criteria:\n\n* Person not affiliated to a social security scheme or beneficiary of such a scheme\n* Patient with another hemopathy or another active cancer at the time of diagnosis\n* Minor patient at diagnosis (\\\u003C 18 years old)\n* Patient not capable or without agreement from the guardian or legal representative","ALL","18 Years",{"count":101,"type":102},70,"ESTIMATED","INTERVENTIONAL",[105],"NA","Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms",[108,109,110,111],"Myeloproliferative Neoplasm","Polycythemia Vera","Essential Thrombocythemia","Primary Myelofibrosis","2025-12-02",{"date":114,"type":115},"2025-12-08","ACTUAL",{"date":117,"type":115},"2024-05-29",{"date":119,"type":102},"2028-10-19",{"name":5,"class":6},3]